Press Archive - Stand Up to Cancer


Read the latest Stand Up To Cancer press releases and announcements to see how we are making an impact.


September 11, 2019

Stand Up To Cancer Hails Dr. Dennis J. Slamon, Pioneer In Modern Treatment of Breast Cancer and Leader SU2C Breast Cancer Dream Team

Stand Up To Cancer (SU2C) congratulates Dennis J. Slamon, MD, PhD, leader of the SU2C Breast Cancer Dream Team, on receiving the 2019 Lasker-DeBakey Clinical Medical Research Award for his development of Herceptin, a targeted treatment for HER2-positive breast cancer.
Read More
August 5, 2019


Read More
July 1, 2019

Add A Name To A Plane: American Airlines Aims To Raise Valuable Funding For Stand Up To Cancer With Plane Naming Campaign

American Airlines will provide a once-in-a-lifetime opportunity to add a loved one’s name to one of its planes in honor of those who are cancer survivors, current cancer fighters and those who lost their battle with cancer.
Read More
June 12, 2019

Drs. Carpten and Pettigrew Are Named to Stand Up To Cancer Scientific Advisory Committee

Stand Up To Cancer (SU2C) with its Scientific Partner, the American Association for Cancer Research (AACR), announced two new members of the SU2C Scientific Advisory Committee (SAC): John D. Carpten, PhD, director of the Institute of Translational Genomics at the Keck School of Medicine of the University of Southern California (USC), and Roderic I. Pettigrew, PhD, MD, chief executive officer of Engineering Health (EnHealth) and executive dean for Engineering Medicine (EnMed), at Texas A&M University.
Read More
June 11, 2019

Stand Up To Cancer Hails FDA Approval of ALPELISIB + FULVESTRANT Combination For Patients With A PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer

Stand Up To Cancer (SU2C) welcomed the recent Food and Drug Administration (FDA) approval of alpelisib in combination with fulvestrant, the first and only new therapy for a difficult to treat form of advanced or metastatic breast cancer in both post-menopausal women and in men.
Read More
May 30, 2019

Stand Up To Cancer – Funded Research To Be Presented At ASCO Annual Meeting May 31 – June 4 in Chicago

Researchers whose work has been supported by Stand Up To Cancer, including Uri Tabori, MD, Hospital for Sick Children, Toronto, and Nabil M. Ahmed, MD, Baylor College of Medicine, will discuss their work in advancing immunotherapy for pediatric brain tumors at the Annual Meeting 2019 of the American Society of Clinical Oncology May 31-June 4 at McCormick Place in Chicago.
Read More
May 2, 2019

“Innovation in Collaboration” among Research Teams Rewarded by Grants from Stand Up To Cancer

Stand Up To Cancer (SU2C) announced five new awards today drawing on the strengths of existing research activities to explore cross-cutting questions that have the potential of opening new paths to improved cancer treatment, according to the American Association for Cancer Research, SU2C’s Scientific Partner.
Read More
April 18, 2019

Stand Up To Cancer, Mastercard & Marvel Studios’ Avengers: Endgame Unite To Help Take Down One Of The Biggest Villains Of All: Cancer

Stand Up To Cancer (SU2C), Mastercard and Marvel Studios’ Avengers: Endgame announced today that they are teaming up to take down one of the biggest villains of all, cancer, with an impactful new Public Service Announcement scheduled to launch in April.
Read More
April 17, 2019

Key Protein A Possible New Target in the Treatment of Pancreatic Cancer Pancreatic Cancer Collective Supports Important Study Published in Nature

Research funded by the Pancreatic Cancer Collective, a partnership between Lustgarten Foundation and Stand Up To Cancer and guided by Dr. Tony Hunter at the Salk Institute was published today in Nature and has found that the interaction between pancreatic stellate cells (PSC’s) and pancreatic cancer cells could be “exploitable” due to the presence of a key protein and lead to the development of new targeted strategies for pancreatic cancer therapy.
Read More
March 31, 2019

Stand Up To Cancer Supported Clinical Trials Seeking To Extend CAR T-cell Therapy to Solid Tumors, Reported at AACR Annual Meeting

Stand Up To Cancer (SU2C) is helping scientists make progress in one of the most important areas of cancer research today: expanding the use of autologous CAR T-cell immunotherapy beyond leukemia and other blood cancers to solid tumors such as osteosarcoma and mesothelioma. If ultimately successful, the research could pave the way for a dramatic expansion of a therapy that has revolutionized treatment of blood malignancies but thus far, has had little impact on the solid tumors that make up most cancer cases.
Read More


Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.

Donate to SU2C using your Mastercard, and Mastercard will match up to $250,000 from 12/10 through 12/31, or until match is fulfilled.* Learn How